Orcrist’s lead program centers on HYC750, an exciting candidate drug for treating a serious and common side-effect of chemotherapy treatment for cancer - suppression of the patients' white blood cell production. Blood cell depletion leaves patients prone to severe, possibly fatal, infections and/or subjects them to treatment modifications that, while assisting in the reconstitution of patients' immune systems, also reduce the benefits of chemotherapy.

White blood cell depletion is a multi-billion dollar market, and initial research has shown that HYC750 has the potential to be a more effective, safe and affordable alternative to current commercially available mobilizers.

Orcrist envisions that HYC750 will prove useful in other indications that would benefit from mobilization and harvesting of stem cells. One such indication is Critical Limb Ischemia, and the company is currently pursuing a co-development agreement with a US-based stem cell company actively working with complimentary technology to evaluate HYC750’s efficacy in this indication.